Intratumoral injection of live attenuated yellow-fever vaccine induces type I IFN and promotes CD8+ T cells infiltration, thereby delaying tumor progression and enhancing the anticancer effects of anti-CD137 immunotherapy [195]. The gene discussed is CD8A; the disease is neoplasm.